Cipher Pharmaceuticals (PHE) Price & Analysis

2 Followers

PHE Stock Chart & Stats

€10.10

€0.40(4.12%)

At close: Jul 24 4:00 PM EDT

€10.10

€0.40(4.12%)

Day’s Range― - ―

52-Week Range€7.00 - €12.20

Previous CloseN/A

Volume0.00

Average Volume (3M)36.00

Market Cap

€264.22M

Enterprise Value€462.58

Total Cash (Recent Filing)€6.41M

Total Debt (Recent Filing)€428.30K

Price to Earnings (P/E)9.8

Beta-0.26

Next Earnings

Aug 11, 2026

EPS Estimate

0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.22

Shares Outstanding25,391,321

10 Day Avg. Volume59

30 Day Avg. Volume36

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)2.22

Price to Sales (P/S)5.44

P/FCF Ratio9.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€13.60

Price Target Upside34.68% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.56

Revenue Forecast (FY)€33.24M

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained very high net margins (~54% TTM) indicate durable pricing power and a favorable product mix in specialty pharmaceuticals. This margin profile supports reinvestment, licensing deals, and margin resilience across cycles, underpinning long-term cash earnings potential.

Strong Cash GenerationRobust operating and free cash flow, with FCF growth ~77% and near 1:1 cash conversion to reported profit, demonstrates persistent ability to self-fund operations, licensing payouts and opportunistic investments without heavy external financing.

Conservative Balance SheetVery low leverage (debt-to-equity ≈0.04) and a growing equity base provide financial flexibility to pursue licensing, M&A or absorb shocks. The conservative capital structure reduces refinancing risk and supports long-term strategic optionality.

Bears Say

Profitability VolatilitySignificant year-to-year swings in margins and net income suggest earnings may be influenced by non-recurring items or product mix shifts. This reduces predictability of future profits and complicates long-term planning, forecasts and investor confidence.

Concentrated, Partner-Dependent ModelBusiness depends on a small portfolio and third-party partners for market access and royalties. Revenue concentration and counterparty risk make top-line and royalty streams sensitive to partner performance, contract terms, and geographic coverage changes.

Variable Cash Coverage / Working CapitalFluctuations in cash conversion and working capital timing have produced inconsistent coverage of accounting profits. This increases the risk of short-term liquidity needs, complicates capital allocation, and may necessitate ad hoc financing during adverse working-capital swings.

Cipher Pharmaceuticals News

Cipher Pharmaceuticals price target raised to C$22 from C$21 at Stifel

Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$22 from C$21 and...

3M ago

CaryHealth launches direct-to-patient program for Cipher’s Natroba

CaryHealth announced the launch of its direct-to-patient platform to support seamless access to Natroba, a prescription treatment for...

4M ago

Cipher Pharmaceuticals price target raised to C$21 from C$20 at Stifel

Stifel raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$21 from C$20 and keeps a Buy...

5M ago

Cipher Pharmaceuticals Delivers Record 2025 Results and Primes for Next Acquisition Phase

Cipher Pharmaceuticals ( ($TSE:CPH) ) has shared an update. Cipher Pharmaceuticals reported record 2025 results, with total revenue...

5M ago

Is CPHRF a Buy, Before Earnings?

Cipher Pharmaceuticals Inc (CPHRF) is scheduled to report 4th quarter earnings on 03/12/2026, after the market closes. Regarding...

5M ago

Cipher Pharmaceuticals Sets March Date for Q4 and Fiscal 2025 Results

Cipher Pharmaceuticals ( ($TSE:CPH) ) has shared an update. Cipher Pharmaceuticals Inc. will release its fourth-quarter and full-year...

5M ago

Cipher Wins Health Canada Review for Natroba Head Lice and Scabies Treatment

Cipher Pharmaceuticals ( ($TSE:CPH) ) just unveiled an update. Cipher Pharmaceuticals has had its new drug submission for...

6M ago

Cipher Pharmaceuticals: Strong Q3 2025 Earnings Call

Cipher Pharmaceuticals Inc (($TSE:CPH)) has held its Q3 earnings call. Read on for the main highlights of the...

9M ago

Cipher Pharmaceuticals Reports Strong Q3 2025 Results

Cipher Pharmaceuticals Inc ( ($CPHRF) ) has released its Q3 earnings. Here is a breakdown of the information...

9M ago

Cipher Pharmaceuticals Reports Strong Q3 2025 Financial Results

Cipher Pharmaceuticals ( ($TSE:CPH) ) has provided an update. Cipher Pharmaceuticals reported a strong financial performance for the...

9M ago

Cipher Pharmaceuticals Achieves Strong Q3 2025 Financial Performance

Cipher Pharmaceuticals ( ($TSE:CPH) ) has issued an update. Cipher Pharmaceuticals reported significant financial growth in the third...

9M ago

Cipher Pharmaceuticals Inc (CPHRF) Q3 Earnings Cheat Sheet

Cipher Pharmaceuticals Inc (CPHRF) is scheduled to report 3rd quarter earnings on 11/06/2025, after the market closes. Regarding...

9M ago

Cipher Pharmaceuticals to Announce Q3 2025 Financial Results

Cipher Pharmaceuticals ( ($TSE:CPH) ) just unveiled an announcement. Cipher Pharmaceuticals announced the release of its third-quarter 2025...

9M ago

Cipher Pharmaceuticals price target raised to C$20 from C$17 at Stifel

Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$20 from C$17 and...

12M ago

PHE FAQ

What was Cipher Pharmaceuticals’s price range in the past 12 months?

Cipher Pharmaceuticals lowest stock price was €7.00 and its highest was €12.20 in the past 12 months.

What is Cipher Pharmaceuticals’s market cap?

Cipher Pharmaceuticals’s market cap is €264.22M.

When is Cipher Pharmaceuticals’s upcoming earnings report date?

Cipher Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.

How were Cipher Pharmaceuticals’s earnings last quarter?

Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported €0.208 earnings per share for the quarter, beating the consensus estimate of €0.117 by €0.091.

Is Cipher Pharmaceuticals overvalued?

According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cipher Pharmaceuticals pay dividends?

Cipher Pharmaceuticals does not currently pay dividends.

What is Cipher Pharmaceuticals’s EPS estimate?

Cipher Pharmaceuticals’s EPS estimate is 0.18.

How many shares outstanding does Cipher Pharmaceuticals have?

Cipher Pharmaceuticals has 25,391,321 shares outstanding.

What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?

Cipher Pharmaceuticals reported an EPS of €0.208 in its last earnings report, beating expectations of €0.117. Following the earnings report the stock price went up 10%.

Which hedge fund is a major shareholder of Cipher Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:PHE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cipher Pharmaceuticals Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€13.60 (34.68% Upside)

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.

Cipher Pharmaceuticals (PHE) Earnings & Revenues

Historic Earnings Reports

PHE Company Deck

PHE Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all DE:PHE earnings summaries

PHE Stock 12 Month Forecast

Average Price Target

€13.60

▲(34.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","8":"€8","10":"€10","12":"€12","14":"€14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.602253939999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.602253939999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.602253939999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,8,10,12,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,10.554019533846155,10.808039067692308,11.062058601538462,11.316078135384615,11.570097669230769,11.824117203076923,12.078136736923076,12.33215627076923,12.586175804615383,12.840195338461537,13.094214872307692,13.348234406153846,{"y":13.602253939999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,10.554019533846155,10.808039067692308,11.062058601538462,11.316078135384615,11.570097669230769,11.824117203076923,12.078136736923076,12.33215627076923,12.586175804615383,12.840195338461537,13.094214872307692,13.348234406153846,{"y":13.602253939999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,10.554019533846155,10.808039067692308,11.062058601538462,11.316078135384615,11.570097669230769,11.824117203076923,12.078136736923076,12.33215627076923,12.586175804615383,12.840195338461537,13.094214872307692,13.348234406153846,{"y":13.602253939999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >